ReviewANZ journal of surgery2025
Contemporary Surgical Management of Colorectal Cancer in Lynch Syndrome: Considering the Implications of Known Genotype.
Review in ANZ journal of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Contemporary Surgical Management of Colorectal Cancer in Lynch Syndrome: Considering the Implications of Known Genotype.ANZ journal of surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLynch syndrome (LS) is an autosomal dominant disorder caused by germline mutations in mismatch repair (MMR) genes, accounting for 1%-3% of all colorectal cancer (CRC) diagnoses. It is associated with an elevated lifetime CRC risk of 30%-80% and predisposes individuals to various extra-colonic malignancies. Advances in genetic profiling have refined our understanding of LS, offering opportunities to tailor surgical and surveillance strategies. SUMMARY: The surgical management of LS is shifting from a uniform, aggressive approach to more nuanced strategies guided by patient-specific factors, including age, tumor characteristics, and genetic variants. While extended resections reduce metachronous CRC risk, they may not significantly improve survival compared to segmental resections and can negatively affect quality of life. Enhanced surveillance and emerging therapies, such as chemoprophylaxis and immunotherapy, are further reshaping treatment paradigms. KEY MESSAGE: Surgical management of LS must remain patient-centered, integrating functional outcomes, genetic risk, and individual circumstances. Genetic-variant-specific recommendations, coupled with personalized surveillance strategies, are essential to optimizing care without compromising survival or quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.